869088-29-9

Basic information

• Product Name: (3-chloro-2-methoxyphenyl)methanol
• Synonyms: (3-chloro-2-methoxyphenyl)methanol
• CAS NO: 869088-29-9
• Molecular Weight: 172.611
• Mol File: 869088-29-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (3-chloro-2-methoxyphenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3-chloro-2-methoxyphenyl)methanol(869088-29-9)
• EPA Substance Registry System: (3-chloro-2-methoxyphenyl)methanol(869088-29-9)

Safety Data

• Hazardous Substances Data: 869088-29-9(Hazardous Substances Data)

Usage

Description

(3-chloro-2-methoxyphenyl)methanol is a chemical compound with the molecular formula C8H9ClO2. It is an organic compound that features a chloro and a methoxy group attached to a phenyl ring, as well as a hydroxyl group attached to a methylene group.
Used in Pharmaceutical Industry:
(3-chloro-2-methoxyphenyl)methanol is used as a precursor in the manufacture of various drugs for its structural features and reactivity.
Used in Chemical Production:
(3-chloro-2-methoxyphenyl)methanol is used as a building block in the production of various chemical products for its versatility.

Upstream product

• 92992-36-4 methyl 3-chloro-2-methoxybenzoate 
• 3260-93-3 3-chloro-2-methoxybenzoic acid 

Downstream Products

• 1044256-94-1 1-(bromomethyl)-3-chloro-2-methoxybenzene 
• 223778-54-9 3-chloro-2-methoxybenzaldehyde 

Relevant articles and documents

N-Arylsulfonyl Indolines as Retinoic Acid Receptor-Related Orphan Receptor γ (RORγ) Agonists

The nuclear retinoic acid receptor-related orphan receptor γ (RORγ; NR1F3) is a key regulator of inflammatory gene programs involved in T helper 17 (TH17) cell proliferation. As such, synthetic small-molecule repressors (inverse agonists) targeting RORγ have been extensively studied for their potential as therapeutic agents for various autoimmune diseases. Alternatively, enhancing TH17 cell proliferation through activation (agonism) of RORγ may boost an immune response, thereby offering a potentially new approach in cancer immunotherapy. Herein we describe the development of N-arylsulfonyl indolines as RORγ agonists. Structure–activity studies reveal a critical linker region in these molecules as the major determinant for agonism. Hydrogen/deuterium exchange coupled to mass spectrometry (HDX-MS) analysis of RORγ–ligand complexes help rationalize the observed results.

Novel compounds

The present invention provides compounds of Formula I wherein R1, R2, R3, and n have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment